Nucala (Mepolizumab) Patent Expiration, LOE Window & CMS Spending
Nucala (Mepolizumab) by GSK: Biologic BLA (Purple Book Regime), 0 AB generics, $454.3M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | GSK |
| FDA Application & Pathway | B125526 (BLA) |
| Exclusivity / Cliff Horizon | Biologic BLA (Purple Book Regime) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | Not listed / N/A |
| Orange Book Patents (*PED Extensions) | 0 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $454.3M |
| 2024 Medicare Part D Spend | $317.9M |
| 2024 Medicaid Spend | $136.4M |
| Reported Wholesale Price Change (CA SB 17) | 4 WAC filings (max 16.5% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for GSK across sibling Meru public-data platforms.